

**AKUH OUTPATIENTS. PERCENT SENSITIVE (number of isolates tested) JAN TO DEC 2025**

Organism	AMK	AMP	AMC	ATM	CFM	CIP	CRO	CT*	CXM	GEN	IPM	MEM	SXT	TZP	NIT†	ETP
<i>E. coli</i>	79.7(2185)	11.5(18034)	42.3(1322)	-	23.8(15734)	27.4(12087)	28(17976)	0 (2000)	9.5 (566)	77.1(17971)	75 (564)#	72.5(509)#	38.9 (18039)	75.8(18017)	84.1 (16117)	88.9(17932)
<i>Enterobacter</i> spp	79 (619)	-	-	-	-	48.9(614)	48.5(619)	0(176)	-	69 (618)	-	-	60.1(611)	61.4(607)	-	71.8(600)
<i>Klebsiella</i> spp	68.4(6877)	-	37.2(6844)	-	-	42(6876)	37.4(6879)	0(2345)	-	72.3(6875)	18.9(1151)#	16.9(1094)#	50.2(6855)	55.8(6845)	-	66.3(6792)
<i>Serratia</i> spp	27.3 (1133)	-	-	-	-	21.8 (1128)	18.6 (1134)	-	-	28.7 (1131)	8.5(710)#	9.4(701)#	37.4(1127)	23.9(1094)	-	26.7(1108)
<i>Proteus mirabilis</i>	70.6(1004)	24.2 (1002)	54.7(1003)	-	-	29 (1000)	52.4 (1002)	-	-	47.9 (999)	-	-	27.6(1002)	-	-	93.7(993)
	AMK	ATM	CAZ	CIP	CT*	GEN	LEV	IMP	MEM	SXT	TET	MINO	TIG	TZP	TOB	
<i>Acinetobacter</i> spp	36.1(2192)	-	27.5(2175)	29.5(2152)	0 (1583)	42.2 (2158)	-	21.9(1883)	21.8 (1988)	32.5 (2171)	-	65.4 (231)	17.2(570)	28.1(2066)	42.4(1596)	
<i>P. aeruginosa</i>	71.5 (1767)	60.7 (5709)	73.8 (7015)	63.7(6818)	0 (2141)	-	-	74(6797)	73.2(6750)	-	-	-	-	75.3 (6790)	73 (6061)	
<i>S. maltophilia</i>	-	-	-	-	-	-	96.2 (342)	-	-	97.1 (344)	-	93.3 (326)	-	-	-	
<i>B. cepacia</i>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	AMP	CLR	CLI	ERY	FD	CIP/LEV	LNZ	TET	SXT	PEN	OX	VAN				
<i>Enterococcus</i> spp	68.9 (3759)	82.7 (1120)	-	-	-	-	87.4 (437)	-	-	-	-	88.9 (3756)				
<i>S. aureus</i>	-	-	67.7 (6081)	34.3(6082)	76.7 (6057)	23.2 (6434)	99.5 (5009)	69.2(5137)	72.2 (6445)	0.1 (5441)	25.2 (6775)	100 (5235)				
CONS	-	-	-	-	-	-	-	-	-	-	-	-				

#Tested only in bacteremic isolates. † Reported for urinary isolates only.

\*Current susceptibility testing guidelines suggest no 'sensitive' category for colistin. Isolates are either intermediate or resistant. Percent resistance rates for colistin are: *Acinetobacter* 3.0; *E. coli* 3.20; *Klebsiella* spp 19; *Enterobacter* spp 8.00; and 0.90 % for *P. aeruginosa* in 2024.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

**Abbreviations:** AMK – Amikacin; AMP – Ampicillin; ATM – Aztreonam; AMC – Amoxicillin/Clavulanate; AZM – Azithromycin; BDQ – Bedaquiline; CAS – Caspofungin; CAZ – Ceftazidime; CFM – Cefixime; CFZ – Clofazimine; CIP – Ciprofloxacin; CL – Clindamycin; CLA – Clarithromycin; CLR – Chloramphenicol; CONS – Coagulase negative staphylococci; CRO – Ceftriaxone; CXM – Cefuroxime; CT – Colistin; ERY – Erythromycin; ETHM – Ethambutol; FLUC – Fluconazole; INH – Isoniazid; FD – Fusidic acid; GEN – Gentamicin; IPM – Imipenem; LEV – Levofloxacin; LNZ – Linezolid; MOX – Moxifloxacin; MTZ – Metronidazole; MEM – Meropenem; MINO – Minoceycline; OX – Oxacillin; OFX – Ofloxacin; PEN – Penicillin; PZA – Pyrazinamide; RIF – Rifampicin; SXT – Co-trimoxazole; TET – Tetracycline; TIG – Tigecycline; TZP – Piperacillin/Tazobactam; TOB – Tobramycin; VAN – Vancomycin; VOR – Voriconazole



**Aga Khan University Hospital**  
**Clinical Laboratory**  
**Microbiology**  
**ANTIBIOTIC SUSCEPTIBILITY REPORT**  
**Jan-Dec 2025**  
 Telephone: 34930051 ext. 1608, 1682

**AKUH OUT-PATIENTS. PRECENT SENSITIVE (number of isolates tested) Jan-dec 2025**

Organism	AMP	ATM	AZM	CAZ	CFM <sup>∞</sup>	CIP	CLR	CRO	CXM	ERY	MEM/IPM	SXT	TET
<i>Campylobacter jejuni/coli</i>	-	-	-	-	-	6.5 (138)	-	-	-	94.2 (138)	-	-	65.9 (138)
<i>Salmonella Paratyphi A</i>	99.8(817)	-	-	-	-	0.6 (817)	99.6 (817)	100 (817)	-	-	-	99.8 (817)	-
<i>Salmonella Typhi</i>	20.2(3326)	-	100(3324)	-	-	0.12(3327)	24.7 (3322)	29.9(3326)	-	-	100 (3324)	25.5(3326)	-
<i>Shigella spp</i>	26.9 (119)	-	85.3 (116)	-	-	48.3 (118)	89.1 (119)	43.7 (119)	-	-	100 (119)	31.1 (119)	-
<i>Vibrio cholerae</i>	11.2 (89)	-	100 (89)	-	-	95.9 (89)	70.8 (89)	-	-	-	-	33.7 (89)	100 (89)
		AMC	CIP	CFM	CLR	CRO	CXM	ERY	SXT	TET	PEN	AZM	
<i>Haemophilus influenzae</i>	84.3(631)	-	57.7(629)	-	93.4(632)	100 (631)	88.9 (629)	-	28(628)	86.2(629)	-	-	
<i>Moraxella catarrhalis</i>	-	96.8 (124)	-	-	-	-	-	84.7 (124)	76.6(124)	86.9 (122)	-	-	
<i>Neisseria gonorrhoeae</i>	-	-	0(36)	100 (36)	-	100 (36)	-	-	-	13.9 (36)	5.6 (36)	100 (36)	
		CLI	CLR	ERY	CXM	LEV/OFX	CRO	PEN	SXT	TET	VAN		
<i>Streptococcus pyogenes (GAS)</i>	42.6 (693)	76 (673)	-	-	89.9 (682)	100 (695)	100 (695)	-	-	100 (696)			
<i>Streptococcus agalactiae (GBS)</i>	39.5 (1035)	75.8(99)	-	-	63.1(1878)	100 (1881)	100 (1880)	-	-	100 (1881)			
<i>Streptococcus pneumoniae</i>	57.4 (486)	95.2 (508)	28.4 (486)	81.3 (390)	91.3(473)	100 (494)	35.1 (482)	15.3 (450)	31.5(465)	100 (507)			
		MTZ	AMC										
<i>Bacteroides spp</i>	36.9(111)	60.7(168)											
<i>Clostridium spp*</i>	54.5(11)	100(18)											
		INH	RIF	PZA	ETHM	LEV	MOX	BDQ	CFZ	LNZ			
<i>Mycobacterium tuberculosis</i>	-	94.3(1094)	94.6(298)	-	79(1094)	80.3(173)	91.8(73)	93.2 (73)	98.6 (73)				
		AMC	AMK	CLA	IPM	CIP	SXT	MOX					
<i>Nocardia spp</i>	14.9(74)	98.7(75)	17.3 (75)	24.3(74)	30.7 (75)	90.8(76)	40 (75)						
		FLU	VOR	CAS									
<i>Candida albicans</i>	98.8(321)	98.7(307)	100(318)										
		FLU	VOR	CAS									
<i>Non-albicans Candida spp</i>	80.8(792)	98.3(642)	100(667)										

<sup>†</sup> = Susceptibility data includes meningitic and non-meningitic isolates. Penicillin susceptibility suggests susceptibility to amoxicillin and ampicillin for treatment of pneumonia cases, as well as to Penicillin G for treatment of meningitis.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

**Note.** <sup>∞</sup>Cefixime is not routinely tested in ampicillin-susceptible isolates of *S. Typhi* and *S. Paratyhi*. The percent susceptibilities may be considered the same as those observed for ceftriaxone

† Organisms with fewer than 30 isolates should be interpreted with caution as small numbers may bias group susceptibilities

\*Does not include or refer to *Clostridium difficile* or *Clostridium tetani*

**Abbreviations:** AMK–Amikacin; AMP–Ampicillin; ATM–Aztreonam; AMC–Amoxicillin/Clavulanate; AZM–Azithromycin; BDQ–Bedaquiline; CAS–Caspofungin; CAZ–Ceftazidime; CFM–Cefixime; CFZ–Clofazimine; CIP–Ciprofloxacin; CLI–Clindamycin; CLA–Clarithromycin; CLR–Chloramphenicol; CONS–Coagulase negative staphylococci; CRO–Ceftriaxone; CXM–Cefuroxime; CT–Colistin; ERY–Erythromycin; ETHM–Ethambutol; FLUC–Fluconazole; INH–Isoniazid; FD–Fusidic acid; GEN–Gentamicin; IPM–Imipenem; LEV–Levofloxacin; LNZ–Linezolid; MOX–Moxifloxacin; MTZ–Metronidazole; MEM–Meropenem; MINO–Minocycline; NIT–Nitrofurantoin; OX–Oxacillin; OFX–Ofloxacin; PEN–Penicillin; PZA–Pyrazinamide; RIF–Rifampicin; SXT–Co-trimoxazole; TET–Tetracycline; TIG–Tigecycline; TZIP–Piperacillin/Tazobactam; TOB–Tobramycin; VAN–Vancomycin; VOR–Voriconazole



Aga Khan University Hospital  
Clinical Laboratory  
Microbiology  
**ANTIBIOTIC SUSCEPTIBILITY REPORT**  
Jan-Dec 2025  
Telephone:34930051 ext.1608,1682